In the past two decades, biopharmaceuticals have been a breakthrough in improving the
quality of lives of patients with various cancers, autoimmune, genetic disorders etc. With the …

Although dry powder inhalers (DPIs) have attracted great interest compared to nebulizers
and metered-dose inhalers (MDIs), drug deposition in the deep lung is still insufficient to …

Abstract Poly-L-lysine (PLL) is a promising candidate for the treatment of pulmonary
infection with lower occurrence of drug-resistance due to its unique antibacterial …

Swellable microparticles (SMs) provide a potential strategy for achieving sustained
inhalation therapy. However, spray dried SMs are highly hygroscopic, exhibiting poor …

Dry powder inhalers (DPI) are widely used systems for pulmonary delivery of therapeutics.
The inhalation performance of DPIs is influenced by formulation features, inhaler device and …

Pulmonary administration of dry powder formulation presents several advantages in the
treatment of respiratory diseases. Since micronized drug particles are very cohesive and …

Netilmicin (NTM) is one of the first-line drugs for lower respiratory tract infections (LRTI)
therapy, but its nephrotoxicity and ototoxicity caused by intravenous injection restrict its …

Previous studies have shown that combining colistin (Col), a cationic polypeptide antibiotic,
with ivacaftor (Iva), a cystic fibrosis (CF) drug, could achieve synergistic antibacterial effects …

The great potential of hydroxypropyl beta-cyclodextrin (HPßCD), as a dried-protein
stabilizer, has been attributed to various mechanisms namely water-replacement, vitrification …

Mucous plugs in the respiratory system of cystic fibrosis patients are often infected, typically
by Pseudomonas aeruginosa. Nebulized levofloxacin is effective against P. aeruginosa, but …